Policymakers are juggling short-term relief measures and longer-term structural reforms aimed at lowering costs, expanding access, and improving outcomes — all while preserving incentives for innovation.
Where the pressure is coming from
Consumers and employers face rising out-of-pocket spending and premiums, driving demand for stronger policy solutions.
At the same time, advances in specialty medicines and biologics introduce high-cost therapies that challenge traditional payment approaches.
That combination pushes leaders to rethink how prices are set, how care is delivered, and how risk is shared across the system.
Policy levers being used and debated
– Price negotiation and purchasing power: Granting a large public purchaser greater negotiating leverage is argued to be one of the most direct ways to lower prices for commonly used medicines. Negotiation can be structured around clinical value, volume, and net prices after rebates.
– Inflation penalties and rebate reforms: Policies that require manufacturers to rebate price increases above inflation or to reform pharmacy benefit manager (PBM) rebate practices aim to reduce perverse incentives that inflate list prices while shifting discounts away from patients.
– International reference pricing and value-based pricing: Some proposals tie domestic prices to prices in peer countries or link payment to real-world outcomes. Both approaches seek better alignment between price and clinical benefit.
– Promotion of generics and biosimilars: Speeding market entry of lower-cost alternatives and tackling barriers to competition helps bring sustainable savings without altering patent or regulatory fundamentals.
– Targeted out-of-pocket caps: Capping patient cost sharing for critical medicines such as insulin or for specialty drugs can ease financial strain for the most vulnerable, although broader cost controls are needed to address system-wide inflation.
Access and delivery reforms
Expanding coverage through public programs and supporting state-level safety nets remain central to improving access. Telehealth policies, expanded behavioral health services, and support for primary care workforce development have been used to connect more people to care, particularly in rural and underserved urban communities. Shifting payment models toward value-based care incentivizes prevention and chronic disease management, which can reduce long-term costs and improve outcomes if implemented with equity safeguards.
Equity and maternal/behavioral health
Addressing racial and socioeconomic disparities — particularly in maternal and behavioral health outcomes — requires coordinated policy attention. Investments in community-based care, supportive social services, and payment models that reward equity-sensitive outcomes are gaining traction as necessary complements to clinical reforms.
What consumers and stakeholders should watch
Legislative and regulatory actions on drug pricing mechanics, PBM transparency, and telehealth reimbursement will strongly influence out-of-pocket costs and provider behavior. Employers and health plans are increasingly experimenting with direct contracting, reference-based pricing, and value-based agreements; those innovations can signal scalable approaches. For individuals, shopping plans carefully, using manufacturer assistance or patient savings programs when appropriate, and advocating with elected officials for affordability measures are practical steps.
Ongoing debate will balance affordability, access, and innovation.
Expect continued policy evolution as stakeholders test new models to make care more affordable and equitable while maintaining a dynamic biomedical sector.